BBIO
Bridgebio Pharma, Inc. Health Care Pharmaceutical Preparations Russell 3000
$74.95Close
$14.6BMarket cap
$61.37 – $90.1752-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Lagging the market RS 46 · weaker than 54% of stocks over 12 months
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
17%
1wk
up 9.3%
price change
1mo
up 13.9%
price change
12-month return
up 18%
market up 11% ·
its own up 2%
F-score
3 / 9
Weak
Altman Z
-3.46
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 3.3%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
up 126%
year on year
EPS growth
—
latest quarter
Sales growth
up 193%
latest quarter · +72 pts
ROE
—
return on equity
Free cash margin
down 89%
-$447.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- took on more long-term debt
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitability improving
- profits backed by cash
- assets working harder
Trade setup
ATR%
3.2%
$2.38 a day · 2×ATR $70.19
RS
46 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
2.3×
vs 50-day average
Up/down volume
0.69
50 sessions
Implied move
—
no scheduled report
Trend template · 4 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: fails
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$2.1B as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.5% over the year, from 190m to 195m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 98.3% to 95.8%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+8% vs market2 sessions after results
Financials
- Gross 96%
- Net -146%
- Free cash -89%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M |
| Gross margin | — | 96% | 96% | 74% | 98% | 96% |
| Operating income | -$474.5M | -$576.6M | -$512.2M | -$607.4M | -$593.0M | -$523.4M |
| Net income | -$505.5M | -$586.5M | -$484.6M | -$653.3M | -$543.3M | -$732.9M |
| Net margin | -6128% | -841% | -624% | -7022% | -245% | -146% |
| Earnings per share | -$4.28 | -$4.06 | -$3.29 | -$4.01 | -$2.92 | -$3.83 |
| Free cash flow | -$407.2M | -$511.2M | -$424.3M | -$529.0M | -$521.7M | -$447.0M |
| Free cash margin | -4937% | -733% | -546% | -5687% | -235% | -89% |
| Cash | $356.1M | $393.8M | $376.7M | $375.9M | $681.1M | $570.1M |
| Long-term debt | $92.4M | $430.8M | $431.0M | $446.4M | $437.3M | $2.0B |
| Shareholders' equity | $57.9M | -$870.4M | -$1.3B | -$1.4B | -$1.5B | -$2.1B |
| Shares outstanding | 122.85m | 147.34m | 150.63m | 175.08m | 190.04m | 194.77m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Oct 29, 2025 | Quarterly ↗ | Sep 30, 2025 | 29d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| Apr 29, 2025 | Quarterly ↗ | Mar 31, 2025 | 29d |
| Feb 20, 2025 | Annual ↗ | Dec 31, 2024 | 51d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Oct 13, 2026 | Other events ↗ |
| Aug 31, 2026 | Other events ↗ |
| Aug 17, 2026 | Material agreement · Other events ↗ |
| Aug 10, 2026 | Results ↗ |
| Jul 22, 2026 | Other events ↗ |
| Jul 2, 2026 | Material agreement · Unregistered share sale · Holder rights changed · Charter or bylaws · Regulation FD ↗ |
| Jun 26, 2026 | Director or officer change · Shareholder vote ↗ |
| May 27, 2026 | Other events ↗ |
| May 13, 2026 | Other events ↗ |
| May 8, 2026 | Material agreement · Agreement ended ↗ |
| May 7, 2026 | Results · Other events ↗ |